Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

2.50
Hdl Handle:
http://hdl.handle.net/2436/621058
Title:
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Authors:
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Parker, Christopher C; Russell, J Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J; Thalmann, George; Amos, Claire; Matheson, David; Millman, Robin; Alzouebi, Mymoona; Beesley, Sharon; Birtle, Alison J; Brock, Susannah; Cathomas, Richard; Chakraborti, Prabir; Chowdhury, Simon; Cook, Audrey; Elliott, Tony; Gale, Joanna; Gibbs, Stephanie; Graham, John D; Hetherington, John; Hughes, Robert; Laing, Robert; McKinna, Fiona; McLaren, Duncan B; O'Sullivan, Joe M; Parikh, Omi; Peedell, Clive; Protheroe, Andrew; Robinson, Angus J; Srihari, Narayanan; Srinivasan, Rajaguru; Staffurth, John; Sundar, Santhanam; Tolan, Shaun; Tsang, David; Wagstaff, John; Parmar, Mahesh K B
Citation:
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial 2016, 387 (10024):1163 The Lancet
Journal:
The Lancet
Issue Date:
Mar-2016
URI:
http://hdl.handle.net/2436/621058
DOI:
10.1016/S0140-6736(15)01037-5
Additional Links:
http://linkinghub.elsevier.com/retrieve/pii/S0140673615010375
Type:
Article
Language:
en
Description:
NCT00268476
ISSN:
01406736
Sponsors:
Cancer Research UK, Medical Research Council, Novartis, Sanofi -Aventis, Pfizer, Janssen, Astellas.
Appears in Collections:
FEHW

Full metadata record

DC FieldValue Language
dc.contributor.authorJames, Nicholas Den
dc.contributor.authorSydes, Matthew Ren
dc.contributor.authorClarke, Noel Wen
dc.contributor.authorMason, Malcolm Den
dc.contributor.authorDearnaley, David Pen
dc.contributor.authorSpears, Melissa Ren
dc.contributor.authorRitchie, Alastair W Sen
dc.contributor.authorParker, Christopher Cen
dc.contributor.authorRussell, J Martinen
dc.contributor.authorAttard, Gerhardten
dc.contributor.authorde Bono, Johannen
dc.contributor.authorCross, Williamen
dc.contributor.authorJones, Rob Jen
dc.contributor.authorThalmann, Georgeen
dc.contributor.authorAmos, Claireen
dc.contributor.authorMatheson, Daviden
dc.contributor.authorMillman, Robinen
dc.contributor.authorAlzouebi, Mymoonaen
dc.contributor.authorBeesley, Sharonen
dc.contributor.authorBirtle, Alison Jen
dc.contributor.authorBrock, Susannahen
dc.contributor.authorCathomas, Richarden
dc.contributor.authorChakraborti, Prabiren
dc.contributor.authorChowdhury, Simonen
dc.contributor.authorCook, Audreyen
dc.contributor.authorElliott, Tonyen
dc.contributor.authorGale, Joannaen
dc.contributor.authorGibbs, Stephanieen
dc.contributor.authorGraham, John Den
dc.contributor.authorHetherington, Johnen
dc.contributor.authorHughes, Roberten
dc.contributor.authorLaing, Roberten
dc.contributor.authorMcKinna, Fionaen
dc.contributor.authorMcLaren, Duncan Ben
dc.contributor.authorO'Sullivan, Joe Men
dc.contributor.authorParikh, Omien
dc.contributor.authorPeedell, Cliveen
dc.contributor.authorProtheroe, Andrewen
dc.contributor.authorRobinson, Angus Jen
dc.contributor.authorSrihari, Narayananen
dc.contributor.authorSrinivasan, Rajaguruen
dc.contributor.authorStaffurth, Johnen
dc.contributor.authorSundar, Santhanamen
dc.contributor.authorTolan, Shaunen
dc.contributor.authorTsang, Daviden
dc.contributor.authorWagstaff, Johnen
dc.contributor.authorParmar, Mahesh K Ben
dc.date.accessioned2018-01-31T14:51:20Z-
dc.date.available2018-01-31T14:51:20Z-
dc.date.issued2016-03-
dc.identifier.citationAddition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial 2016, 387 (10024):1163 The Lanceten
dc.identifier.issn01406736-
dc.identifier.doi10.1016/S0140-6736(15)01037-5-
dc.identifier.urihttp://hdl.handle.net/2436/621058-
dc.descriptionNCT00268476en
dc.description.sponsorshipCancer Research UK, Medical Research Council, Novartis, Sanofi -Aventis, Pfizer, Janssen, Astellas.en
dc.language.isoenen
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0140673615010375en
dc.rightsArchived with thanks to The Lanceten
dc.subjectprostate canceren
dc.subjectADTen
dc.subjectmetastasisen
dc.titleAddition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialen
dc.typeArticleen
dc.identifier.journalThe Lanceten
All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.